TUMOR BIOLOGY AND MICROENVIRONMENT (TBM) ? ABSTRACT The Tumor Biology and Microenvironment (TBM) Program is a translational science program that aims to discover the cellular and molecular determinants that drive the initiation and progression of cancers through interactions with their microenvironments and develop and test innovative diagnostic and treatment strategies. This highly integrated Program includes 37 members from 13 departments and 4 schools at Wayne State University. TBM Program members, who conduct basic, preclinical, and clinical research, receive $4,468,183 in peer reviewed, cancer-related grant support, of which $1,943,419 is from the NCI. The TBM Program is organized along three major themes. The goal of the first theme is to explore biological processes that mediate the phenotypical plasticity, proliferation, and survival of tumor cells. Translational research is conducted to evaluate the potential clinical application of these molecular determinants as tumor markers and/or therapeutic targets. The second theme investigates mechanisms that enable tumor cells to overcome external barriers during invasion and metastasis. Our investigators assess the importance of factors that control extracellular proteolysis and signaling mechanisms that are being used by tumor cells to adapt to and subvert the microenvironment at primary and metastatic sites. The objective of the third theme is to develop new strategies to engage the immune system as powerful defenses against cancer. Research activities include the development of immune modulators and novel vehicles to optimally deliver immunotherapeutics, as well as the use of state-of-the art imaging modalities for monitoring the success to tumor immunotherapy. The TBM Program is led by Dr. Kay-Uwe Wagner as Program Leader and Dr. Asfar Azmi as Program Co-Leader. The Leader and Co-Leader are new since the last competitive renewal. All members of the TBM Program actively collaborate with members of the MI, MT, and PSDR Programs at KCI. Of the 484 manuscripts published between December 2015 and November 2019, 41% and 44% were intra- and inter-programmatic, respectively, and 61% were multi-institutional collaborations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
United States
Zip Code
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642
Ahmed, Zainab Sabry Othman; Li, Xin; Li, Feng et al. (2018) Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells. J Cell Biochem 119:9006-9016
Beebe-Dimmer, Jennifer L; Albrecht, Terrance L; Baird, Tara E et al. (2018) The Detroit Research on Cancer Survivors (ROCS) Pilot Study: A focus on outcomes after cancer in a racially-diverse patient population. Cancer Epidemiol Biomarkers Prev :
Desai, Pinkal; Wallace, Robert; Anderson, Matthew L et al. (2018) An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort. Cancer Med 7:2121-2130
White, Donna L; Hoogeveen, Ron C; Chen, Liang et al. (2018) A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Med 7:2180-2191

Showing the most recent 10 out of 826 publications